PFE QuantSignals V3 Earnings 2025-11-03 PFE Earnings Signal | 2025-11-03 • Direction: BUY CALLS | Confidence: 72% • Entry Plan: Open | Expiry 2025-11-07 • Strike Focus: $24.50 • Entry Range: $0.47 • Target 1: $0.94 • Stop Loss: $0.28 • Implied Move: $1.12 (4.6%) • 24h Move: +0.06% • Flow Intel: Bullish (Low P/C Ratio) | PCR 0.48 • ⚠️ MODERATE RISK WARNING: Consider reducing position size due to moderate confidence level. • Earnings Date: 2025-11-04 | Estimate: $0.64 ⚖️ Compliance: Educational earnings analysis for QS Premium members only. Not financial advice. 🎯 TRADE RECOMMENDATION Direction: BUY CALLS Confidence: 72% Conviction Level: HIGH 🧠 ANALYSIS SUMMARY Katy AI Signal: NEUTRAL with 50% confidence - limited directional bias but earnings guidance strongly favors calls Technical Analysis: Price consolidating at $24.57 with bearish EMA alignment and neutral RSI (51.4). Volume at 0.4x average indicates low pre-earnings participation, suggesting potential for explosive move post-earnings News Sentiment: High-impact news surrounding Pfizer's acquisition battle with Novo Nordisk for Metsera - creates uncertainty but highlights Pfizer's aggressive growth strategy Options Flow: Strongly bullish with P/C ratio of 0.48 indicating heavy call buying. Maximum volume at $24 call strike shows institutional positioning for upside Risk Level: MODERATE - Low volume and neutral technicals create uncertainty, but strong earnings history and bullish options flow provide conviction 💰 TRADE SETUP Expiry Date: 2025-11-07 (4 days) Recommended Strike: $24.50 Entry Price: $0.46 - $0.49 Target 1: $0.94 (100% gain from entry) Target 2: $1.41 (200% gain from entry) Stop Loss: $0.28 (40% loss from entry) Position Size: 3% of portfolio ⚡ COMPETITIVE EDGE Why This Trade: Exceptional 100% earnings beat rate with average 43.1% surprise provides statistical edge. Options flow Image QS Analyst APP — 10:52 AM shows smart money positioning for upside breakout Timing Advantage: Earnings release creates immediate catalyst with implied 4.6% move potential. Current low volume suggests underappreciated setup Risk Mitigation: Conservative delta (0.538) provides good probability while allowing for 100-200% return targets. Stop loss protects against earnings disappointment 🚨 IMPORTANT NOTES Katy AI shows neutral technical bias (50% confidence) - trade relies heavily on earnings history and options flow signals Acquisition battle news creates headline risk - monitor pre-market reaction to earnings and any Metsera-related announcements Low pre-earnings volume indicates potential for larger-than-expected move in either direction Consider scaling into position to manage earnings volatility risk 📊 TRADE DETAILS 📊 🎯 Instrument: PFE 🔀 Direction: CALL (LONG) 🎯 Strike: 24.50 💵 Entry Price: 0.47 🎯 Profit Target: 0.94 🛑 Stop Loss: 0.28 📅 Expiry: 2025-11-07 📏 Size: 3.0 📈 Confidence: 72% ⏰ Entry Timing: N/A 🕒 Signal Time: 2025-11-03 13:52:32 EST ⚠️ MODERATE RISK WARNING: Consider reducing position size due to moderate confidence level.

Pfizer “shows its claws”: between litigation and the search for a new boost By Ion Jauregui – Analyst at ActivTrades Pfizer (NYSE: PFE) is back in Wall Street’s spotlight after filing a lawsuit against Metsera (NASDAQ: MTSR) and Novo Nordisk (CPH: NOVOb), accusing them of breaching a merger agreement and acting in bad faith. The pharmaceutical giant, which had already obtained early regulatory clearance in the U.S., maintains that its deal with Metsera remains valid and seeks to block the biotech from accepting Novo’s rival offer. The dispute opens a new chapter in the fierce battle for the highly profitable obesity treatment market. The fundamental front: pressure to reinvent itself After the boom in vaccine and antiviral revenues during the pandemic, Pfizer is going through a readjustment phase. Its latest results show annual revenue of around $63.8 billion, with a net profit of about $10.7 billion, while its operating margin stands near 17%. However, the decline in Paxlovid and Comirnaty sales has exposed its dependence on the COVID segment. The company’s expansion strategy through acquisitions — such as the failed Metsera deal, if the lawsuit does not prevail — is key to diversifying its portfolio. The biotech firm is seen as a valuable asset in the obesity drug market, a segment dominated by Novo Nordisk and Eli Lilly with blockbuster products like Wegovy and Mounjaro. In terms of valuation, Pfizer trades at a P/E ratio of 13, a relatively low level compared with peers, reflecting market skepticism but also some appeal for value investors. Its balance sheet remains solid, with a moderate debt-to-equity ratio (0.65×) and a stable dividend policy offering a yield close to 6% annually. Technical analysis (Ticker AT: PFE.US) From a technical standpoint, Pfizer’s stock is trading around $24.6, moving sideways throughout 2025. The price remains near its current control point area, while moving averages indicate the possible start of a bullish trend. Key levels to watch are $24.16 and $23.23 as short-term supports, with the next major trend support located at $21.72. A sustained breakout above $26.11 could push prices toward this year’s highs at $27.69, with further resistance levels at $28.43 and $29.47. A confirmed break above the $27 zone would reinforce this bullish scenario. Conversely, losing the mentioned support levels could open the door to new annual lows. The RSI stands at a neutral 48.33%, while the MACD continues to show a slightly negative bias. The ActivTrades US Market Pulse indicator sits in a neutral-risk zone, suggesting that the market currently reflects this sideways consolidation phase. Outlook Pfizer’s lawsuit could reshape its strategic future: if the company manages to uphold the Metsera agreement, it would strengthen its pipeline and its position within the metabolic segment. However, the legal process could be prolonged, adding short-term uncertainty. Pfizer is “showing its claws” at a critical juncture — caught between the pressure to reinvent its business and the need to prove to investors that its best medicine remains its ability to adapt. ******************************************************************************************* The information provided does not constitute investment research. The material has not been prepared in accordance with the legal requirements designed to promote the independence of investment research and such should be considered a marketing communication. All information has been prepared by ActivTrades ("AT"). The information does not contain a record of AT's prices, or an offer of or solicitation for a transaction in any financial instrument. No representation or warranty is given as to the accuracy or completeness of this information. Any material provided does not have regard to the specific investment objective and financial situation of any person who may receive it. Past performance and forecasting are not a synonym of a reliable indicator of future performance. AT provides an execution-only service. Consequently, any person acting on the information provided does so at their own risk. Political risk is unpredictable. Central bank actions can vary. Platform tools do not guarantee success.

Hey traders, it’s Alfonso Moreno from Set and Forget! Today, I’m diving into one of the most famous pharmaceutical giants on the planet — Pfizer. Yes, that Pfizer. Love them or hate them, the chart doesn’t lie. The weekly timeframe just gave us a brand-new demand imbalance, and it’s looking ready to roar. Let’s break it down and see if Pfizer could be preparing for a bullish comeback. The New Weekly Demand Imbalance We’ve got a fresh weekly demand imbalance trading between $24.39 and $23.58, and it’s already gained control. This is the largest bullish candlestick in months — a clear reaction showing professional buying pressure stepping in after months of drifting lower. The beauty of this setup? The risk is under $1, which makes it a tight and well-defined imbalance — a pocket of price where institutions previously decided to buy aggressively.

NYSE:PFE after breaking out on trump deal and now working with him to sell their products through TrumpRx launching next year. They are also exempt from tariffs for 3 years and plan to invest 60B in the US. good support/resistance flip could take place here would like to hold 25 but 24 is possible. Next stop $30 could take a while. They've gotten hammered past 4 years the momentum up will be strong. I did well with ATM calls last run up will probably do it again month or two out.

Pfizer, Inc (Wave analysis) Daily - 1/10/2025 Update Chart has language

Pfizer Inc. (PFE) and Other Pharmaceutical Stocks Rise Following Trump’s Decision According to media reports, US President Donald Trump launched a website allowing Americans to purchase medicines directly. He announced that Pfizer would offer some of its drugs on this platform and introduce new medicines to the US market at reduced prices. Trump added that his administration is working with other companies, including Eli Lilly, to reach “similar agreements.” Reports state that Pfizer’s deal with the Trump administration will enable patients to receive significant discounts. In return, the company will receive a three-year exemption from any tariffs. The news pushed pharmaceutical stocks to the top of yesterday’s gainers list: → Pfizer Inc. (PFE) rose by 6.8% → Merck & Co Inc. (MRK) rose by 6.8% → Eli Lilly and Co. (LLY) rose by 5.0% Technical analysis of the PFE chart The chart indicates that: → In the long term, PFE’s share price remains in a bearish trend, highlighted by the descending orange channel. → However, in April the stock reached its lowest level in nearly 13 years, after which the price began showing an upward trajectory, forming higher highs and higher lows within the ascending blue channel. A strong fundamental driver yesterday caused PFE’s share price to rebound sharply from the lower boundary of the blue channel towards its median, encountering little resistance when breaking through the September local barrier at $24.75. It is possible that positive market sentiment will persist and be leveraged by bulls to extend the rally. However, the real test of their resolve might come at resistance near the summer highs around $26.00. A more substantial obstacle might lie in the $27–27.50 area, where multiple resistances converge, including: → the upper boundaries of both the blue and orange channels; → key highs from the first half of 2025. Nonetheless, assuming the fundamental backdrop continues to be supported by positive news on progress in cancer treatments (Pfizer is conducting large-scale developments in this area, aided by its acquisition of Seagen, a pioneer in antibody-drug conjugates, or ADCs), this could lead to an attempt to break the long-term downward trend as early as this year. This article represents the opinion of the Companies operating under the FXOpen brand only. It is not to be construed as an offer, solicitation, or recommendation with respect to products and services provided by the Companies operating under the FXOpen brand, nor is it to be considered financial advice.

This giant might not make you rich, but its in my opinion a safe bet for 2025>2026. I have personally opened a long position due to my analysis. Check my old bitcoin predictions from 4 years ago and you will see my eye is strong for longer term moves. Make your own analysis and decision, this is just my personal approach. Take care and trade safe.

📍 **To see my confluences and/or linework:** Step 1: Grab chart 📊 Step 2: Unhide Group 1 in object tree 🎯 Step 3: Hide and unhide specific confluences one by one ✨ Step 4: Double-click the screen to show RSI, MFI, CVD, and OBV indicators alongside divergence markings 📈 Title: 💊 PFE: Bears Trapped at Multi-Year Lows - Spring Ready to Uncoil The Market Participant Battle: Bears have systematically beaten bulls into submission at the $24 level, creating a compression zone where institutional buyers are quietly accumulating positions. The repeated tests at this proven support level (points 2 and 4 on the chart) demonstrate that smart money is defending this zone aggressively. With RSI and MFI showing bullish divergence while price makes lower lows, the bears have overextended their hand. Price is expected to spring back toward the $25.50-$26.00 resistance zone as trapped shorts cover and sidelined bulls rush back in. Confluences: Confluence 1: Proven Market Players Pattern (Points 1-4) The chart reveals a sophisticated accumulation pattern where point 3 closing above point 1 confirms point 2 as a proven market player zone. Point 4's return to this level, combined with bullish divergences across multiple indicators, suggests institutional defenders have established a floor. The pattern indicates smart money has been systematically absorbing selling pressure at these levels, setting up for a powerful reversal. Confluence 2: Multiple Bullish Divergences While price created a lower low at point 4, RSI, MFI, and CVD all printed higher lows - a triple divergence rarely seen at market bottoms. The RSI has entered oversold territory below 30, while MFI shows accumulation despite price weakness. This divergence cluster signals exhausted selling pressure and hidden institutional buying beneath the surface. Confluence 3: Statistical Extremes & Harmonic Patterns Price has dropped below the 1st standard deviation and bounced, showing potential institutional entries. The presence of two harmonic patterns (Leonardo and Bat) both projecting upside targets adds geometric confluence to the reversal thesis. The OBV touching the lower Bollinger Band at point 4 indicates selling volume extremes typically associated with reversals. Confluence 4: Breakout from Strong Downtrend The successful breakout from the descending channel, followed by a backtest that holds above the breakout level, represents a classic trend reversal setup. The 5th standard deviation reaction using the major trend provides a statistical edge for mean reversion traders. Web Research Findings: - Technical Analysis: PFE holds support from accumulated volume at $24.04 with potential for an upward reaction when this support is tested . Current price sits precisely at this critical level. - Recent Earnings: Q2 2025 earnings showed revenue of $14.65 billion, up 10% year-over-year, with adjusted EPS of $0.78 beating expectations of $0.58 - Analyst Sentiment: Of 15 analysts covering Pfizer, the stock receives a consensus "Hold" rating with a one-year price target of $28.08, representing 14.19% upside potential - Data Releases & Economic Calendar: Next earnings report scheduled for November 4, 2025, with potential catalyst for movement - Interest Rate Impact: The Fed cut rates by 25 basis points to 4.0-4.25%, with lower rates generally supporting pharmaceutical stocks through reduced borrowing costs and improved valuations Layman's Summary: Pfizer's stock is sitting at a crucial support level that has held multiple times before. The company is making more money than expected, beating earnings estimates significantly. While analysts are cautiously optimistic with price targets around $28 (about 17% higher than current levels), the technical setup suggests the stock is oversold and due for a bounce. Recent Fed rate cuts should help pharmaceutical companies like Pfizer by making it cheaper to borrow money for research and operations. The combination of strong support, oversold indicators, and improving fundamentals creates a favorable risk/reward setup for a potential bounce trade. Machine Derived Information: - Image 1: 4-hour chart showing channel patterns with numbered pivot points - Significance: Confirms the participant battle narrative with clear support/resistance zones - AGREES ✔ - Image 2: Clean V-bottom pattern from point 2 to 3 - Significance: Demonstrates powerful reversal capability from these levels - AGREES ✔ - Image 3: Multiple indicator divergences (RSI, MFI, CVD, OBV) - Significance: Extreme oversold conditions with bullish divergences signal imminent reversal - AGREES ✔ - Image 4: Leonardo and Bat harmonic patterns with trend analysis - Significance: Multiple geometric patterns converging at current levels project upside targets - AGREES ✔ Actionable Machine Summary: All four charts unanimously support the bullish reversal thesis. The proven market player pattern, combined with extreme oversold readings and multiple bullish divergences, creates a high-probability bounce setup. The harmonic patterns provide clear upside targets around $25.50-$26.00, offering a favorable 1:2 risk/reward ratio with stops below $23.50. The technical evidence strongly suggests bears have exhausted their ammunition at these levels. Conclusion: Trade Prediction: SUCCESS Confidence: High The convergence of proven support levels, multiple bullish divergences, harmonic patterns, and improving fundamentals creates a compelling long setup. With RSI oversold, institutional accumulation patterns evident, and analyst targets 17% higher, the risk/reward heavily favors the bulls. Key catalyst: Any positive news or market strength should trigger short covering and propel price toward $25.50-$26.00 initial targets.

Current Price: $23.76 Direction: SHORT Targets: - T1 = $22.50 - T2 = $21.50 Stop Levels: - S1 = $24.50 - S2 = $25.30 **Wisdom of Professional Traders:** This analysis synthesizes insights from thousands of professional traders and market experts who have been following Pfizer’s recent struggles. Combining the collective intelligence of skilled professionals helps pinpoint high-probability trade setups that align with developing market sentiment. Currently, the consensus among traders suggests that Pfizer could continue facing downside pressure due to deteriorating fundamentals and bearish technical indicators. **Key Insights:** Pfizer has encountered significant revenue headwinds in 2025, primarily stemming from the expiration of patents on key drugs and muted vaccine demand. Reduced fulfillment for COVID-related products has weighed heavily on the company's earnings potential, leading to revised guidance for the fiscal year. Additionally, increasing competition in the immunology and oncology spaces further pressures Pfizer's growth story as it strives to pivot toward pipeline development and innovation for long-term recovery. From a technical perspective, Pfizer's stock remains bearish after failing to hold a support level above $25 earlier this month. The stock’s Relative Strength Index (RSI) lands below 40, suggesting persistent oversold conditions, while volume data confirms the dominance of sellers. With its 50- and 200-day moving averages trending downward, a continued bearish trend appears probable ahead of Pfizer’s next earnings release in Q4. Traders report resistance near $25.50, a level the stock is struggling to reclaim, setting the stage for further declines. **Recent Performance:** Pfizer’s stock has dropped substantially over the last quarter, declining roughly 16% from its 2025 peak of $28. The healthcare sector as a whole has been underperforming, with Pfizer particularly impacted due to broader market rotations favoring cyclical stocks amidst elevated interest rates. The stock’s downward trajectory reflects clear institutional selling, particularly in high-volume days driving prices lower. This sustained weakness positions the stock deep below critical moving average levels—a bearish signal for technical traders. **Expert Analysis:** Market analysts have downgraded expectations for Pfizer’s year-end financial results. Rising R&D expenses alongside declining margins are seen as major obstacles for the company, even as it doubles down on its strategic initiatives like mRNA vaccine development and oncology advancements. Technical professionals highlight that the break below $25 signals bearish momentum, with lower highs and consistent failures to reverse selling pressure confirming short-term downside risk. Traders also note a bearish MACD crossover, reinforcing negative sentiment and suggesting further weakness. **News Impact:** Pfizer’s recent restructuring plans and ongoing cost-cutting measures have dominated headlines but failed to instill confidence among investors. The company faces growing skepticism regarding its ability to sustain long-term growth in core areas like immunology. Additionally, disappointing data on COVID-19 vaccine-related revenue has underscored challenges in adapting to waning pandemic-related demand. These developments are fostering bearish sentiment and keeping downward pressure on the stock. **Trading Recommendation:** Pfizer’s sustained weakness presents a compelling short opportunity for traders looking to capture downside potential. The break below key support levels, coupled with bearish technical signals and disappointing fundamentals, suggests the stock could revisit targets in the $22-$21 range. Initiating a short position at current levels could deliver a favorable risk-reward setup, particularly with stop-loss levels firmly placed above $24.50 and $25.30 to mitigate potential reversals. Short sellers can leverage this momentum to capitalize on further downside risks. Do you want to save hours every week? Register for the free weekly update in your language!

Pfizer has spent almost two years consolidating after a major slide. Now some traders may see the long-term downtrend reasserting itself. The first pattern on today’s chart is the pair of highs in July and August just above $26, which could be viewed as a double-top reversal pattern. Second, the drugmaker made a series of higher lows since May. It closed yesterday under that trendline: a potential bear-flag breakdown. Third, the 50-, 100- and 200-day simple moving averages are close to each other. That illustrates the long period of consolidation, which may open the door to renewed movement. Fourth, MACD is falling and the 8-day exponential moving average (EMA) is below the 21-day EMA. Those signals could suggest that bears are taking control in the short-term. Next, technicians may see odds favoring a retest of April’s low under $21. Finally, PFE is an active underlier in the options market. (It trades more than 100,000 contracts per session, according to TradeStation data.) That could help traders take positions with calls and puts. TradeStation has, for decades, advanced the trading industry, providing access to stocks, options and futures. If you're born to trade, we could be for you. See our Overview for more. Past performance, whether actual or indicated by historical tests of strategies, is no guarantee of future performance or success. There is a possibility that you may sustain a loss equal to or greater than your entire investment regardless of which asset class you trade (equities, options or futures); therefore, you should not invest or risk money that you cannot afford to lose. Online trading is not suitable for all investors. View the document titled Characteristics and Risks of Standardized Options at www.TradeStation.com . Before trading any asset class, customers must read the relevant risk disclosure statements on www.TradeStation.com . System access and trade placement and execution may be delayed or fail due to market volatility and volume, quote delays, system and software errors, Internet traffic, outages and other factors. Securities and futures trading is offered to self-directed customers by TradeStation Securities, Inc., a broker-dealer registered with the Securities and Exchange Commission and a futures commission merchant licensed with the Commodity Futures Trading Commission). TradeStation Securities is a member of the Financial Industry Regulatory Authority, the National Futures Association, and a number of exchanges. Options trading is not suitable for all investors. Your TradeStation Securities’ account application to trade options will be considered and approved or disapproved based on all relevant factors, including your trading experience. See www.TradeStation.com . Visit www.TradeStation.com for full details on the costs and fees associated with options. Margin trading involves risks, and it is important that you fully understand those risks before trading on margin. The Margin Disclosure Statement outlines many of those risks, including that you can lose more funds than you deposit in your margin account; your brokerage firm can force the sale of securities in your account; your brokerage firm can sell your securities without contacting you; and you are not entitled to an extension of time on a margin call. Review the Margin Disclosure Statement at www.TradeStation.com . TradeStation Securities, Inc. and TradeStation Technologies, Inc. are each wholly owned subsidiaries of TradeStation Group, Inc., both operating, and providing products and services, under the TradeStation brand and trademark. When applying for, or purchasing, accounts, subscriptions, products and services, it is important that you know which company you will be dealing with. Visit www.TradeStation.com for further important information explaining what this means.